Abstract
Hypothetical proteins (HPs) are non-predicted sequences that are identified only by open
reading frames in sequenced genomes, but their protein products remain uncharacterized by any
experimental means. The genome of every species consists of HPs that are involved in various cellular
processes and signaling pathways. Annotation of HPs is important as they play a key role in
disease mechanisms, drug designing, vaccine production, antibiotic production, and host adaptation.
In the case of bacteria, 25-50% of the genome comprises HPs, which are involved in metabolic
pathways and pathogenesis. The characterization of bacterial HPs helps to identify virulent proteins
that are involved in pathogenesis. This can be done using in-silico studies, which provide sequence
analogs, physiochemical properties, cellular or subcellular localization, structure and function validation,
and protein-protein interactions. The most diverse types of virulent proteins are exotoxins,
endotoxins, and adherent virulent factors that are encoded by virulent genes present on the chromosomal
DNA of the bacteria. This review evaluates virulent HPs of pathogenic bacteria, such as
Staphylococcus aureus, Chlamydia trachomatis, Fusobacterium nucleatum, and Yersinia pestis. The
potential of these HPs as a drug target in bacteria-caused infectious diseases, along with the mode of
action and treatment approaches, has been discussed.
Keywords:
Hypothetical proteins, pathogenesis, virulence, bacteria, viruses, drug.
Graphical Abstract
[3]
Naveed, M.; Chaudhry, Z.; Ali, Z.; Amjad, M. Annotation and curation of hypothetical proteins: Prioritizing targets for experimental study. Adv. Life Sci., 2018, 5(3), 73-87.
[16]
Kumar, K.; Prakash, A.; Anjum, F.; Islam, A.; Ahmad, F.; Hassan,
M. I. Structure-based functional annotation of hypothetical proteins
from Candida dubliniensis: A quest for potential drug targets. 3
Biotech, 2015, 5(4), 561-576.
[22]
School, K.; Marklevitz, J.; Schram, K. Predictive characterization
of hypothetical proteins in Staphylococcus aureus NCTC 8325 Bioinformation,
2016, 209-220.
[33]
Gnanamani, A.; Hariharan, P.; Paul-Satyaseela, M. Staphylococcus
aureus: Overview of bacteriology, clinical diseases, epidemiology,
antibiotic resistance and therapeutic approach. In: Frontiers in Staphylococcus
aureus; Enany, S.; Alexander, L.C., Eds.; IntechOpen:
London, 2017; pp. 4-28.
[51]
Hafner, L.M.; Timms, P. Development of a vaccine for Chlamydia trachomatis: Challenges and current progress. Vaccine (Auckl.), 2015, 5, 45-58.
[60]
Yang, Y.; Weng, W.; Peng, J.; Hong, L.; Yang, L.; Toiyama, Y.; Gao, R.; Liu, M.; Yin, M.; Pan, C. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor− κB, and up-regulating expression of microRNA-21. Gastroenterology, 2017, 152(4), 851-866.
[67]
Vlăsceanu, G.M.; Holban, A.M.; Grumezescu, A.M. 9 - Alternative
strategies to reduce the incidence of severe infections. In: Biofilms
and Implantable Medical Devices; Deng, Y.; Lv, W., Eds.; Woodhead
Publishing: Sawston, 2017; pp. 195-221.
[79]
Sun, W.; Six, D.A.; Reynolds, C.M.; Chung, H.S.; Raetz, C.R.H.; Curtiss, R. Pathogenicity of Yersinia pestis synthesis of 1-dephosphorylated lipid A. Infect. Immun., 2013, 81(4), 1172-1185.
[88]
Dean, D. Chlamydia trachomatis Pathogenicity and Disease. In:
Chlamydial Infection: A Clinical and Public Health Perspective;
Black, C.M., Ed.; Karger: Basel, 2013; 7, pp. 25-60.